Bevacizumab Concomitant with Chemotherapy is Effective in Treating Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer |
Sun, Jing
(Department of Medical Oncology, Chinese PLA General Hospital)
Hu, Yi (Department of Medical Oncology, Chinese PLA General Hospital) Wu, Bai-Shou (Department of Medical Oncology, Chinese PLA General Hospital) Wang, Jin-Liang (Department of Medical Oncology, Chinese PLA General Hospital) Tao, Hai-Tao (Department of Medical Oncology, Chinese PLA General Hospital) Zhang, Su-Jie (Department of Medical Oncology, Chinese PLA General Hospital) |
1 | Cirillo M, Venturini M, Ciccarelli L, et al (2009). Clinician versus nurse symptom reporting using the National Cancer Institute Common Terminology Criteria forAdverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol, 20, 1929-35. DOI |
2 | Cohen MH, Shen YL, Keegan P, et al (2009). FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblas-toma multiforme. Oncologist, 14, 1131-8. DOI |
3 | Crino L, Dansin E, Garrido P, et al (2010). Safety and efficacy of first-line bevacizumab-based therapy in advanced nonsquamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol, 11, 733-40. DOI |
4 | Eisenhauer EA, Therasse P, Bogaerts J et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. DOI ScienceOn |
5 | Emal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-249. DOI ScienceOn |
6 | Ferrara N, Hillan KJ, Gerber HP et al (2004). Discovery and development of bev-acizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391-400. DOI ScienceOn |
7 | Habib S, Delourme J, Dhalluin X, Petyt G et al (2013). Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study. Lung Cancer, 80, 197-202. DOI |
8 | Heist RS, Fidias P, Huberman M et al (2008). Aphase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol, 3, 1153-8. DOI |
9 | Herbst RS, O'Neill VJ, Fehrenbacher L et al (2007). Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol, 25, 4743-50. DOI ScienceOn |
10 | Huang XE, Tian GY, Cao J, et al (2013). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7. 과학기술학회마을 DOI ScienceOn |
11 | Johnson DH, Fehrenbacher L, Novotny WF et al (2004). Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 22, 2184-91. DOI ScienceOn |
12 | Juergens R, Brahmer J (2007). Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how? Curr Oncol Rep, 9, 255-64. DOI |
13 | Kerbel R, Folkman J (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer, 2, 727-39. DOI ScienceOn |
14 | Kitamura K, Kubota K, Ando M, Takahashi S et al (2013). Bevacizumab plus chemotherapy for advanced nonsquamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol, 71, 457-61. DOI |
15 | Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-8. 과학기술학회마을 DOI ScienceOn |
16 | Lilenbaum R, Raez L, Tseng J, et al (2008). Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol, 3, 511-5. DOI |
17 | Liu HZ, Peng J, Zheng F, et al (2013). Lack of assocation of glutathione S-transferase T1 gene null and susceptibility to lung cancer in china: a meta-analysis. Asian Pac J Cancer Prev, 14, 7215-9. 과학기술학회마을 DOI ScienceOn |
18 | Ma CH, Jiang R, Li JD, et al (2013). Experimental study of Endostar injection concomitant with cryoablation on lung adenocarcinoma A549 xenografts. Asian Pac J Cancer Prev, 14, 6697-701. 과학기술학회마을 DOI |
19 | Niho S, Kunitoh H, Nokihala H, et al (2012). Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small cell lung cancer. Lung Cancer, 76, 362-7. DOI |
20 | Reck M, Von-Pawel J, Zatloukal P, et al (2009). Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall- cell lung cancer: AVAiL. J Clin Oncol, 27, 1227-34. DOI ScienceOn |
21 | Reck M, von Pawel J, Zatloukal P, et al (2010). Overall survival with cisplatin gemcitabine and bevacizumab or placebo as first-line therapy for non squamous non-small cell lung cancer: results from a randomized phase III trial (AVAIL). Ann Oncol, 21, 1804-9. DOI |
22 | Soerjomataram L, Lortet-Tieulent J, Parkin DM, et al (2012). Global burden of cancer in 2008, a systematic analysis of disabelity-adjusted life-year in 12 world regions. Lancet, 380, 1840-50. DOI ScienceOn |
23 | Sandler A, Gray R, Perry MC et al (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355, 2542-50. DOI ScienceOn |
24 | Sandler A, Yi J, Hambleton J, et al (2010). Treatment outcome by tumor histology in Easten Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplation (PC) for advanced non-small cell lung cancer (NSCLC). J Thorac Oncol, 5, 16-23. |
25 | Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. DOI ScienceOn |
26 | Stinchcombe TE, Socinski MA (2009). Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc, 6, 233-41. DOI ScienceOn |
27 | Summers J, Cohen MH, Keegan P, et al (2010). FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. Oncologist, 15, 104-11. DOI |
28 | Wang H, Gui SY, Chen FH, et al (2013). New insights into 4-amino-2-tri-fluoromethyl-phenyl ester inhibition of cell growth and migration in the A549 lung adenocarcinoma cell line. Asian Pac J Cancer Prev, 14, 7265-70. 과학기술학회마을 DOI ScienceOn |
29 | Wu W, Xu L, Liu Z, et al (2009). Acceptable safety of bevacizumab therapy in combination with chemotherapy in patients with advanced lung cancer. Zhongguo Fei Ai Za Zhi, 12, 231-5. |
30 | Xu TP, Zhu CH, Zhang J, et al (2013). MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pac J Cancer Prev, 14, 7085-90. 과학기술학회마을 DOI ScienceOn |
31 | Zhang XJ, Zhang TY, Yu FF, et al (2013). Risk of treatmentrelated mortality with sorafenib in patients with cancer. Asian Pac J Cancer Prev, 14, 6681-6. DOI |
32 | Mohammad RY, Somayyeh G, Gholamreza H, et al (2013). Diosgenin inhibits hTERT gene expression in the A549 lung cancer cell line. Asian Pac J Cancer Prev, 14, 6945-8. 과학기술학회마을 DOI ScienceOn |
33 | Adjei AA, Mandrekar SJ, Dy GK et al (2010). Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol, 28, 614-9. DOI |